In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 32.8%. VYGR’s earnings beat ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in previously-untreated non-small cell lung cancer (NSCLC), with numerically higher ...

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...

(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line treatment of adult patients with primary advanced or ...

Approval based on RUBY Part 1 trial, which showed a median overall survival (OS) of 44.6 months for Jemperli plus chemotherapy vs. 28.2 months for chemotherapy alone · Jemperli plus chemotherapy ...